Corbus Pharmaceuticals Holdings, Inc.
CRBP
$8.88
-$0.18-1.93%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 117.54% | 98.84% | 92.77% | 78.84% | 3.38% |
| Gross Profit | -117.54% | -98.84% | -92.77% | -78.84% | -3.38% |
| SG&A Expenses | -7.78% | -2.10% | 18.28% | 20.99% | 18.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.81% | 61.91% | 63.97% | 54.41% | 8.08% |
| Operating Income | -72.81% | -61.91% | -63.97% | -54.41% | -8.08% |
| Income Before Tax | -95.32% | -74.45% | -65.72% | -48.97% | 9.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.32% | -74.45% | -65.72% | -48.97% | 9.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.32% | -74.45% | -65.72% | -48.97% | 9.85% |
| EBIT | -72.81% | -61.91% | -63.97% | -54.41% | -8.08% |
| EBITDA | -74.44% | -63.35% | -65.41% | -55.57% | -8.32% |
| EPS Basic | -63.07% | -17.43% | 18.15% | 39.37% | 64.71% |
| Normalized Basic EPS | -51.33% | -24.42% | 12.51% | 34.66% | 61.55% |
| EPS Diluted | -63.07% | -17.43% | 18.15% | 39.37% | 64.71% |
| Normalized Diluted EPS | -51.33% | -24.42% | 12.51% | 34.66% | 61.55% |
| Average Basic Shares Outstanding | 22.29% | 36.67% | 72.40% | 121.36% | 151.68% |
| Average Diluted Shares Outstanding | 22.29% | 36.67% | 72.40% | 121.36% | 151.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |